The American Journal of Medicine
Volume 121, Issue 6, Supplement , Pages S30-S34 , June 2008

Intensifying Treatment in Poorly Controlled Type 2 Diabetes Mellitus: Case Reports

  • Joseph Tibaldi, MD

      Affiliations

    • Corresponding Author InformationRequests for reprints should be addressed to Joseph Tibaldi, MD, Queens Diabetes and Endocrinology Associates, 59-45 161 Street, Flushing, New York 11365, USA.

References 

  1. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–412
  2. Wright A, Burden AC, Paisey RB, et al. UK Prospective Diabetes Study Group Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK Prospective Diabetes Study (UKPDS 57). Diabetes Care. 2002;25:330–336
  3. Melander A, Donnelly R, Rydberg T. Is there a concentration-effect relationship for sulphonylureas?. Clin Pharmacokinet. 1998;34:181–188
  4. Stenman S, Melander A, Groop P-H, Groop LC. What is the benefit of increasing the sulfonylurea dose?. Am Intern Med. 1993;118:169–172
  5. Hermann LS, Schersten B, Melander A. Antihyperglycaemic efficacy, response prediction, and dose-response relations of treatment with metformin and sulphonylurea, alone and in primary combination. Diabet Med. 1993;11:953–960
  6. Goldberg RB, Holvey SM, Schneider J Glimepiride Protocol #201 Study Group. A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. Diabetes Care. 1996;19:849–856
  7. Garber A, Duncan TG, Goodman AM, et al. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med. 1997;103:491–497
  8. Noble J, Baerlocher MO, Silverberg J. Management of type 2 diabetes mellitus: role of thiazolidinediones. Can Fam Physician. 2005;51:683–687
  9. Nissen SE, Wolsky K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. [published correction appears in N Engl J Med. 2007;357:100] N Engl J Med. 2007;356:2457–2471
  10. Highlights of prescribing information for Avandia. Research Triangle Park, NC: GlaxoSmithKline http://www.fda.gov/cder/foi/label/2007/021071s031lbl.pdfAccessed December 13, 2007
  11. Nathan DM, Buse JB, Davidson MB, et al. Professional Practice Committee, American Diabetes Association and the European Association for the Study of Diabetes Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2006;49:1711–1721
  12. Ratner RE, Maggs D, Nielsen LL, et al. Long-term effects of exenatide therapy over 82 weeks on glycaemic control and weight in over-weight metformin-treated patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2006;8:419–428
  13. Mikhail N. Exenatide: a novel approach for treatment of type 2 diabetes. South Med J. 2006;99:1271–1279
  14. Nauck MA, Duran S, Kim D, et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia. 2007;50:259–267
  15. Lindholm A. New insulins in the treatment of diabetes mellitus. Best Pract Res Clin Gastroenterol. 2002;16:475–492
  16. Riddle MC, Rosenstock J, Gerich J Insulin Glargine 4002 Study Investigators. The Treat-to-Target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26:3080–3086
  17. Hermansen K, Davies M, Derezinski T, et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naïve people with type 2 diabetes. Diabetes Care. 2006;29:1269–1274
  18. Philis-Tsimikas A, Charpentier G, Clauson P, et al. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther. 2006;28:1569–1581
  19. Eliaschewitz FG, Calvo C, Valbuean H, et al. HOE 901/4013 LA Study Group Therapy in type 2 diabetes: insuling glargine vs. NPH insulin both in combination with glimepride. Arch Med Res. 2006;37:495–501
  20. Davies M, Storms F, Dhutler S, et al. ATLANTUS Study Group Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care. 2005;28:1282–1288
  21. Shapiro AMJ, Meneghini L, Koenen C, et al. PREDICTIVE 303: a 26-week multi-centre, randomized, open-label study to evaluate the efficacy and safety of a simplified self-adjusted dosing guideline using once-daily insulin detemir in patients with type 2 diabetes. Diabet Med. 2006;23(suppl 4):337;Poster 934
  22. Raskin P, Allen E, Hollander P, et al. INITIATE study group Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care. 2005;28:260–265
  23. Klein O, Lynge J, Endahl L, et al. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes Metab. 2007;9:290–299
  24. Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes. 2000;49:2142–2148
  25. Plank J, Bodenlenz M, Sinner F, et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care. 2005;28:1107–1112
  26. Heise T, Nosek L, Ronn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes. 2004;53:1614–1620
  27. Massi Benedetti M, Humburg E, Dressler A, et al. 3002 Study Group A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Horm Metab Res. 2003;35:189–196
  28. Garber A, Wahlen J, Wahl T, et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (the 1-2-3 Study). Diabetes Obes Metab. 2006;8:58–66
  29. Liebl A, Prager R, Kaiser M, et al. PREFER study group Biphasic insulin aspart 30 (BIAsp30), insulin detemir (IDet) and insulin aspart (IAsp) allow patients with type 2 diabetes to reach A1C target: the PREFER Study. [abstract] Diabetes Care. 2006;55(suppl 1):A123

 Statement of author disclosure: Please see the Author Disclosures section at the end of this article.

PII: S0002-9343(08)00311-2

doi: 10.1016/j.amjmed.2008.03.024

The American Journal of Medicine
Volume 121, Issue 6, Supplement , Pages S30-S34 , June 2008

Article Tools